RNTX

DEFA14A - Rein Therapeutics, Inc. (0001420565) (Filer)

DEF 14A - Rein Therapeutics, Inc. (0001420565) (Filer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

PRE 14A - Rein Therapeutics, Inc. (0001420565) (Filer)

Total gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters' over-allotment option. The financing included new and existing healthcare-focused investors

10-Q - Rein Therapeutics, Inc. (0001420565) (Filer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

SCHEDULE 13G - Rein Therapeutics, Inc. (0001420565) (Subject)

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

424B5 - Rein Therapeutics, Inc. (0001420565) (Filer)

AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with patients being added on a regular basisClinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2

S-1 - Rein Therapeutics, Inc. (0001420565) (Filer)

10-K/A - Rein Therapeutics, Inc. (0001420565) (Filer)

10-K - Rein Therapeutics, Inc. (0001420565) (Filer)

AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that it has dosed the first patient in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. This milestone follows the FDA's recent clearance to resume the Phase 2 program and reflects Rein's successful efforts to address the Agency's requests and advance the trial. The Phase 2 study is a randomized, double-blind, place

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

AUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that it has received orphan drug designation from the European Medicines Agency (EMA) for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis (IPF). The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) and subsequent adoption by the European Commission, recognizing both the seriousness of IPF and the need for

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

10-Q - Rein Therapeutics, Inc. (0001420565) (Filer)

AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation study of Rein's lead drug candidate, LTI-03, in idiopathic pulmonary fibrosis (IPF). The preprint, titled "Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study," was authored by an international team of investigators, including Philip L. Molyneaux, MD, Nikhil A. Hi

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)